Primary biliary cholangitis (PBC) is often associated with other autoimmune diseases, but little is known about the infl uence of thyroid disease (TD) on the natural history of PBC. Our aim is to analyze the association between PBC and TD, and the latter's impact on the natural history of PBC at two European centers.
INTRODUCTION
Primary biliary cholangitis (formerly named primary biliary cirrhosis, PBC) is a chronic liver disease characterized by progressive immune-mediated destruction of the small-to-medium-sized bile ducts, resulting in chronic cholestasis, portal infl ammation and, eventually, cirrhosis ( 1 ) . It mainly aff ects middle-aged women, and frequently coexists with various autoimmune diseases. Th e probability of PBC being associated with at least one autoimmune disorder is reportedly as high as 61.1% ( 2 ) , and thyroid diseases (TD) are one of the most common associations with PBC. Crowe et al. ( 3 ) reported positivity for thyroid antibodies in 25 of 95 patients with PBC (26%); and 13 of these patients had biochemical evidence of thyroid dysfunction, usually hypothyroidism (32%). A positive correlation emerged with thyroid antibodies and sicca syndrome, but not with histological stage of PBC. Elta et al. ( 4 ) studied thyroid metabolism in 58 patients with PBC and found a 22% prevalence of hypothyroidism.
Th e prevalence of TD in PBC reportedly ranges between 7.24 and 14.4% (2) (3) (4) (5) , the most oft en encountered thyroid dysfunction being Hashimoto's thyroiditis. TDs are also commonly associated with primary sclerosing cholangitis ( 6 ) , and autoimmune hepatitis ( 7, 8 ) . Th e frequency of TD in autoimmune liver diseases is substantially higher than in the general population. Since fatigue, lethargy, anorexia, and hypercholesterolemia are common features of both hypothyroidism and PBC, patients with PBC should be screened for evidence of TD ( 5 ) . In addition, little attention has been paid in the literature to the infl uence of TD on the natural history of PBC. Th e aim of the present study conducted at two European centers was to analyze the association between PBC and TD, and the impact of the latter on the natural history of PBC.
METHODS
All PBC patients were seen prospectively and included in a database . A detailed description of our recruitment methods and diagnostic and follow-up criteria is available elsewhere ( 9 ) . Th e present study concerns all consecutive PBC patients collected between 1975 and February 2015 who had a follow-up of at least 1 year. PBC was diagnosed on the basis of an antimitochondrial antibody (AMA) positivity higher than 1:40, abnormal alkaline phosphatase levels (at least 1.5 times the norm), and/or a compatible liver histology. Th e AMA-negative variant was diagnosed in patients with abnormal alkaline phosphatase levels (at least 1.5 times the norm), an antinuclear antibody positivity of at least 1:40, and a liver histology compatible with PBC. In AMA-negative patients, biliary tree patency was assessed by ultrasound and nuclear magnetic resonance imaging with cholangiography. Histological staging was done according to Scheuer's classifi cation ( 10 ) .
Th e diagnosis of Hashimoto's thyroiditis was established from a combination of clinical features, the presence of serum antibodies against thyroid antigens (mainly thyroperoxidase and thyroglobulin), and thyroid sonography ( 11 ) . Graves' disease was diagnosed in the presence of one or more of the following features in a thyrotoxic patient: detectable thyroid antibodies in the serum; evidence of ophthalmopathy and/or dermopathy; and diff use and increased thyroid radio-iodine uptake ( 12 ) . Multinodular goiter was diagnosed on the basis of a clinical assessment, including physical examination; ultrasound; fi ne-needle aspiration biopsy to exclude malignancy; and serum TSH assay to assess thyroid function ( 13 ) .
Patient follow-up and event assessment
All patients were assessed at 4-to 6-monthly intervals at the outpatients clinic by the same dedicated staff , who recorded clinical signs and symptoms of liver disease and extrahepatic autoimmunity, and laboratory parameters including aspartate aminotransferase, alanine aminotransferase, gamma-glutamyl transferase, bilirubin, prothrombin time, alkaline phosphatase, serum albumin, IgG, IgA, IgM, total cholesterol, platelet and leukocyte counts, and hemoglobin. Alpha-fetoprotein was assessed every 6 months in patients with features of advanced disease. Liver ultrasound was performed annually in patients in the precirrhotic stage, and every 6 months in those in histological stage IV. From 1987 onwards, all patients were treated with ursodeoxycholic acid (UDCA) at a dose of 15 mg/kg/day. Only eight patients with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA) were treated with prednisolone or prednisone, tapered to a maintenance dose of 7.5 mg/day. Patients with hepatitis B or C infections were excluded for the purposes of this study. Fatigue was assessed in 339 subjects using the PBC-40 questionnaire, a fully validated, PBC-specifi c multidomain tool assessing quality of life ( 14 ) ; fatigue was scored on a 5-point scale (≤11=absent; 12-23=mild; 24-34=moderate; 35-45=severe; >45=extreme).
Th e mean follow-up was 126.9±91.7 months. Th e onset of major complications during the follow-up was classifi ed as follows: HCC was diagnosed by ultrasound (US), computed tomography (CT), or nuclear magnetic resonance imaging (NMRI), as appropriate; ascites was identifi ed clinically or by abdominal US; gastrointestinal bleeding due to portal hypertension was confi rmed by endoscopy in cases of esophageal or gastric varices, or hypertensive gastropathy; portal-systemic encephalopathy was established from clinical parameters according to the West Haven criteria ( 15 ) . Th e study was approved by the local ethical committee and all participants gave their informed consent to the study.
Statistical analyses
Standard descriptive statistics were used to describe the sample's characteristics. Th e chi-squared test was used to test for diff erences in categorical variables between two independent groups, as appropriate, and Student's t -test was used for diff erences in continuous variables between two independent groups. A logistic regression analysis was run (with 95% confi dence intervals). Survival was analyzed with Kaplan-Meier curves (Breslow Generalized Wilcoxon test), and Cox's proportional model was applied in order to determine the presence of independent risk factors that may infl uence survival besides the presence of thyroid dysfunctions. A P value ≤0.05 was considered statistically signifi cant. Th e statistical analysis was conducted using SPSS soft ware (Chicago, IL, USA). Table 1 shows the clinical characteristics of the study group. Th e two series of patients had similar demographic and clinical characteristics, except for smoking habit, with signifi cantly more smokers in Padova than in Barcelona (19.9 vs. 12.9%, P <0.05). Th ere were more patients in histological stage III in Padova than in Barcelona (25.8 vs. 10.6%, P <0.05). Th ere was no diff erence between the two cohorts regarding the prevalence of decompensation events during the follow-up (ascites, variceal bleeding, spontaneous bacterial peritonitis, hepatic encephalopathy, and hepatocellular carcinoma).
RESULTS
Among the 921 PBC patients, 150 (16.3%) had an associated TD, 117/921 (12.7%) with and 33/921 (3.6%) without an autoimmune etiology. No signifi cant diff erences emerged between the two cohorts regarding the presence of TD. Overall, 94 patients (10.2%) had Hashimoto's thyroiditis, 15 (1.6%) had Graves' disease, 22 (2.4%) had multinodular goiters, 7 (0.8%) had thyroid cancer, and 12 (1.3%) had other forms of TD. Autoimmune TD was identifi ed in 117 PBC patients (78% of the 150 patients with associated TD), with a similar prevalence in the two cohorts (78.6 and 77.5% in Padova and Barcelona, respectively). Table 2 shows the diff erent types of TD in the study population and for the two cohorts. Th e prevalence of the diff erent types of TD was similar in Padova and Barcelona, except for Graves' disease and thyroid cancer, which were both more common in the Padova cohort (15.7 vs. 5.0%, and 8.6 vs. 1.3%, respectively; P <0.05). Th e diff erence in the thyroid cancer rate between the two cohorts is further discussed below. Among the 150 PBC patients with TD, 34 (22.6%) had been diagnosed with TD before their PBC was diagnosed, whereas 116 (77.4%) developed TD during their follow-up for PBC.
No diff erences emerged in the biochemical data between patients with and without TD at the time of their PBC being diagnosed ( Table 3 ) . Fatigue was recorded in 86 patients with associated TD (57.3%), and in 410 patients without TD (53.2%); the diff erence was not statistically signifi cant. A sub-analysis on fatigue was performed in 339 patients in the Barcelona cohort, using the PBC-40, a self-administered questionnaire validated for PBC. No diff erences emerged between patients with and without TD in terms of the association with fatigue (either as a symptom per se , or classifi ed by severity (data not shown). No diff erences were found between PBC patients with or without TD regarding liver decom- ( 19 ) . Th e rate of responders ranged between 67 and 83% ( Table 4 ) . No signifi cant diff erence in the response rate was found between patients with and without associated TD ( Table 4 ).
In our study population, 147 patients died during the follow-up, 66 (21.3%) in Padova and 81 (18.2%) in Barcelona ( P =n.s.). Th e mean global transplant-free survival rate was 314.4±9.2 months. Th e mean transplant-free survival rate of PBC patients with and without associated TD was 345.4±21.6 months, and 305.8±10.1 months, respectively; the diff erence was not signifi cant ( Figure 1 ). Using Cox's regression analysis, adjusted for sex and age, survival was not infl uenced by any associated TD or another extrahepatic autoimmune condition, SLE or scleroderma/CREST or RA, smoking habit or alcohol consumption (>40 g/day), or histological stage at diagnosis ( Table 5 ) . Survival was also similar in patients with and without TD, irrespective of their response to UDCA ( P =n.s.)
Th e overall survival rate was similar in the two cohorts in Padova and Barcelona, but when patients without TD were considered separately, those in the Padova cohort had a signifi cantly lower survival rate than those in Barcelona (248.2±14.3 vs. 320.3±9.3 months, P =0.001).
DISCUSSION
Th e results of our study confi rm that TD are oft en associated with PBC, especially Hashimoto's thyroiditis, which shares an autoimmune etiology with PBC. Th ere were no substantial diff erences in the prevalence-incidence of TD among PBC patients at the two European centers investigated. More importantly, the presence of TD in a PBC patient did not infl uence the rate of hepatic complications or response to UDCA treatment. Indeed, the clinical Floreani et al.
and Barcelona. Th e rate of multinodular goiter in the general population varies considerably by geographical area, depending mainly on the population's iodine intake. Both Padova and Barcelona are mildly iodine-defi cient areas. Th e Whickham study found a 5.9% prevalence of multinodular goiter in the UK ( 22 ) . We found a signifi cant diff erence in the prevalence of GD between the two centers considered (0.7% in Barcelona, 2.9% in Padova; P <0.05). Th ese fi gures are much the same as the prevalence of GD in the general population in Spain, and slightly higher than the 1.85% for the population at large in Italy ( 21 ) . Th e prevalence of thyroid cancer was also higher in the PBC cohort than in the general population in Padova, confi rming a previously reported observation ( 27 ) , whereas the prevalence of thyroid cancer in the Barcelona cohort was negligible (0.2%). It may be that the higher prevalence of thyroid cancer in the Italian cohort refl ects the geographical distribution of this neoplasm: Italy has one of the highest incidences of thyroid cancer (19.6 per 100,000 person years in females), whereas the incidence of this cancer in Spain is more than halved (7.8 per 100,000 person years in females) ( 28 ) . Th ese fi gures, drawn from the two countries' national cancer registries, suggest that thyroid cancer might have no correlation with PBC.
Our study showed that an associated TD had no infl uence on the natural history of PBC or on patient survival. When our two cohorts were considered separately, the presence of TD correlated with a better survival for PBC patients in Padova, but not in Barcelona, but the limited information available on the causes of death prevented us from investigating this issue adequately. It should be noticed that treatment with levothyroxine (used to correct clinical hypothyroidism) signifi cantly aff ects a patient's infl ammatory profi le, reducing the pro-infl ammatory cytokines, increasing IL-10 levels, and lowering serum IgG concentrations ( 29, 30 ) . Levothyroxine therapy might therefore improve coronary microvascular function and thereby prevent cardiovascular events (31) (32) (33) .
Th e present study has some obvious limitations. In particular, the study design suff ers from some methodological bias: the database was collected on the grounds of the same criteria, and all medical histories were checked by consulting patients' medical records concerning thyroid dysfunction, but this procedure was not standardized. In addition, the lack of data on causes of death should be considered a bias in our survival analysis.
In conclusion, TDs-and particularly HT-are oft en associated with PBC, but do not infl uence the rate of hepatic complications or the natural history of the latter disease.
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Th e prevalence of TD is estimated to be higher in the PBC population than in the general population both in Italy and in Spain, though no specifi c epidemiological data on autoimmune and nonautoimmune TDs have been published for these two European countries to date. As expected, Hashimoto's thyroiditis (HT) was the most common TD in both cohorts (11.2% in Padova and 9.5% in Barcelona). Two small studies reported a 3.5% prevalence of HT in Spain ( 20 ) , and 5% in Italy ( 21 ) . It has been estimated that up to 5% of the general population have autoimmune TD ( 22, 23 ) . In the Whickham study, conducted in Northern England, the prevalence of spontaneous hypothyroidism from Hashimoto's thyroiditis was 15/1,000 in women (who were diagnosed at a mean 57 years of age), and less than 1/1,000 in men ( 22 ) . In a 3-year survey of 1,457,036 inhabitants of a city in Sweden, the incidence of Graves' disease (GD) was 24.5/100,000 a year, and the condition peaked among those aged 30-39 years ( 24 ) . To date, no published studies have reported on the prevalence of non-autoimmune thyroid conditions in PBC.
Th e HT rate in our sample was similar to the prevalence previously reported in other PBC series from diff erent geographical areas ( 7, 25, 26 ) , and in other autoimmune disorders as well. Th e high prevalence of HT in autoimmune diseases, including PBC, may refl ect a common pathogenic mechanism targeting diff erent organs. In fact, the probability of a patient with PBC having another autoimmune disorders is as high as 61.1% ( 2 ) . On the other hand, multinodular goiter showed an overall prevalence of 2.4% in the PBC population, with no signifi cant diff erence between Padova 
